A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.


Updates from The Motley Fool

Latest updates on Peregrine Pharmaceuticals from Fool.com.  The Fool has written over 100 articles on Peregrine Pharmaceuticals.


Stock Performance

View Interactive PPHM Charts
Sponsored by

Key Data Points

Primary metrics and data points about Peregrine Pharmaceuticals.
Current Price: $0.71
Prev Close: $0.71
Open: $0.70
Bid: $0.68
Ask: $0.71
Day's Range: $0.69 - $0.72
52wk Range: $0.28 - $0.77
Volume: 948,071
Avg Vol 5,479,229
Market Cap: $211M
P/E (ttm): -4.38
EPS (ttm): ($0.16)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Peregrine Pharmaceuticals.
CAPS Rating 1 out of 5
 
128 Outperform
29 Underperform
CAPS All Stars
 
10 Outperform
14 Underperform

How do you think Peregrine Pharmaceuticals will perform against the market?



You pick for Peregrine Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Steve King, CEO

76% Approve

Based on 12 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Peregrine Pharmaceuticals.

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers